ORENCIA(Abatacept) Instructions:Uses,Dosage, Side Effects

1 / 1

ORENCIA(Abatacept)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Bristol-Myers Squibb

Formulation:

INJECTION

Validity period:

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

ORENCIA (abatacept) is an immunomodulatory biologic agent designed to treat autoimmune diseases by selectively modulating T-cell activation. Its unique mechanism involves inhibiting the CD80/CD86-CD28 costimulatory signal required for T-cell activation, helping reduce inflammation and prevent further tissue damage in diseases like rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis. It is also used as a prophylactic measure for acute graft-versus-host disease (aGVHD) in patients undergoing hematopoietic stem cell transplantation.

ORENCIA can be administered either intravenously or subcutaneously, with dosing tailored to the patient's and condition. The drug provides critical therapeutic benefits in the management of chronic autoimmune conditions and plays an essential role in transplant-related complications. Regular monitoring of patients is recommended due to potential adverse effects, including infections and hypersensitivity reactions.

Generic name

ORENCIA(Abatacept)

English name

Abatacept

Alternative Names

ORENCIA

Drug prices

Indications

ORENCIA is indicated for the treatment of: Adults with moderately to severely active rheumatoid arthritis (RA);Pediatric patients ≥2 years of age with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA);Adults and pediatric patients ≥2 years of age with active psoriatic arthritis (PsA);Prophylaxis of acute graft-versus-host disease (aGVHD) in patients ≥2 years undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1-allele mismatched unrelated donor, in combination with a calcineurin inhibitor and methotrexate.

Therapeutic Target

CD80/CD86 on antigen-presenting cells (APCs), inhibiting their interaction with CD28 on T cells—thereby modulating T cell activation and downstream inflammatory responses.

Active Ingredients

Abatacept (a selective costimulation modulator—recombinant fusion protein composed of the extracellular domain of human CTLA-4 linked to a modified Fc portion of human IgG1).

Dosage form

INJECTION

specifications

125mg*4vials/box

Description

Abatacept is a biologic disease-modifying antirheumatic drug (bDMARD) classified as a selective T-cell costimulation modulator. It is a fusion protein composed of the extracellular domain of CTLA-4 linked to an IgG1 Fc fragment. It functions by inhibiting T cell activation, a critical event in the pathogenesis of autoimmune diseases and graft rejection.

Dosage and Administration

1. For RA and PsA (Adults, IV Use):

1.1 Administer at Weeks 0, 2, and 4, then every 4 weeks

1.2 Dosage by body weight:<60 kg: 500 mg (2 vials);60–100 kg: 750 mg (3 vials);100 kg: 1,000 mg (4 vials)

1.3 Infusion time: 30 minutes

1.4 Subcutaneous Use (RA and PsA):125 mg once weekly,IV loading dose optional for RA; not required for PsA

2. For pJIA (≥6 years, IV Use):<75 kg: 10 mg/kg;≥75 kg: Adult dosing

2.1 Administer on Days 0, 14, 28, then every 4 weeks

2.2 Subcutaneous Use (pJIA/PsA, ≥2 years):10–<25 kg: 50 mg;25–<50 kg: 87.5 mg;≥50 kg: 125 mg

2.3 Weekly administration:aGVHD Prophylaxis (IV):≥6 years: 10 mg/kg (max 1,000 mg) on Day –1, +5, +14, +28;2–<6 years: 15 mg/kg (Day –1), 12 mg/kg (Days +5, +14, +28)

2.4 Infusion time: 60 minutes

CATEGORY NAVIGATION